Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study.
Oncologist
; 29(3): 272-274, 2024 Mar 04.
Article
em En
| MEDLINE
| ID: mdl-38243388
ABSTRACT
Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Weighted Assessment Tool score improved by 57.4% and mean percent body surface area involved improved by 52%. Median progression-free survival was 10.3 months. Adverse events occurred in 4 of 7 patients, the most common being fatigue (2/7; grades 1-2), nausea (2/7; grades 1-2), and transaminitis (2/7; grade 3). Overall, low-dose duvelisib showed efficacy for advanced MF with less toxicity, providing a rationale for its use as monotherapy and potentially combinatorial therapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Purinas
/
Neoplasias Cutâneas
/
Micose Fungoide
Tipo de estudo:
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Oncologist
Ano de publicação:
2024
Tipo de documento:
Article